NVIDIA AI Podcast How Bristol Myers Squibb Is Accelerating Drug Development With AI - Ep. 264
21 snips
Jul 9, 2025 Greg Meyers, the Executive VP and Chief Digital and Technology Officer at Bristol-Myers Squibb, shares insights on how AI is reshaping drug development. He discusses transitioning from traditional methods to data-driven discoveries, enhancing the development of breakthroughs like a sickle cell treatment. The conversation explores the company's internal AI tools for over 25,000 employees, alongside the benefits of predictive models. Meyers also addresses challenges in healthcare data and highlights the potential of AI in streamlining clinical trials and improving patient care.
AI Snips
Chapters
Transcript
Episode notes
AI Revolutionizes Drug Discovery
- AI transforms drug discovery from guesswork to data-driven precision.
- It uncovers hidden biological patterns beyond human perception capabilities.
AI-Designed Sickle Cell Therapy
- Bristol Myers Squibb designed a protein therapy for sickle cell using AI.
- AI helped engineer specificity to target disease-causing proteins without off-target effects.
AI Boosts Drug Discovery Efficiency
- Predictive models in AI significantly boost drug discovery success rates.
- AI integration has shortened drug development timelines by enabling better experiment selection.